IDH-Wildtype Glioblastoma
The study used newly diagnosed IDH-wildtype glioblastoma under the WHO 2021 classification as its disease definition. Immunotherapy has limited proven clinical benefit in IDH-wildtype glioblastoma outside small molecularly defined subgroup…
1 sources - 4 claims
The study used newly diagnosed IDH-wildtype glioblastoma under the WHO 2021 classification as its disease definition. Immunotherapy has limited proven clinical benefit in IDH-wildtype glioblastoma outside small molecularly defined subgroups. IDH-wildtype glioblastoma has an immunosuppressive tumor microenvironment and substantial heterogeneity. The curated study cohort contained 176 patients with matched transcriptomic and imaging data.